Join our newsletter

Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM

APILAM informs you that the personal data that you provide to us by filling in this form will be treated by APILAM as responsible for this web. The purpose of the collection and processing of personal data that we request is to manage the registration of this subscription and send periodic bulletins with information and prospective offer of products or services.

Legitimation: Consent of the interested party

As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).

The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.

You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.

You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.

Last update June 10, 2018

Cu-64

High Risk

Poorly safe. Evaluate carefully. Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives). Read the Comment.

Copper 64 (Cu-64) is an unstable isotope of copper which emits positrons.
It is used in medicine for diagnostic purposes (positron emission tomography, PET) and radiation therapy for cancer treatment (Pfeifer 2012, Holland 2009).

Although copper has an average biological life of 18 to 24 days, the radioactive decay half-life of the Cu-64 is 12.7 hours.
Other copper isotopes are also used for diagnostic purposes: Cu-60, Cu-61 and Cu-62 with a radioactive decay half-life of 24 minutes, 3.3 hours and 10 minutes respectively, and in radiotherapy: Cu-67 with a radioactive decay half-life of 62 hours (Follacchio 2017).

Since the last update date we have not found published data on its excretion in breastmilk.

Timings for halting breastfeeding or avoiding close contact are calculated so that the infant is not exposed to more than 1 millisievert (1 mSv = 0.1 rem) of radiation (ICRP 2008, Howe 2008, Stabin 2000). An adult receives between 5 and 10 mSv per year from environmental radiation.
After a period of 10 half-lives of the isotope, all traces of radioactivity will have disappeared in the body.

If you want to continue breastfeeding it is advisable to express and conserve breastmilk in a freezer during the days or weeks prior to administering Cu-64. After the test, express milk for 10 half-lives (127 hours, 5 days), feeding in the meantime using the milk previously stored. Milk expressed after the test can be stored in a separate drawer in the freezer and re-used once 10 half-lives (5 days) have passed.

Try using the radionuclide which has the shortest life.

See below the information of this related product:

Positron Emission Tomography ( Poorly safe. Evaluate carefully. Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives). Read the Comment.)

Alternatives

Fludeoxyglucose F18 ( Poorly safe. Evaluate carefully. Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives). Read the Comment.)
Raclopride 11C ( Poorly safe. Evaluate carefully. Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives). Read the Comment.)

Very Low Risk

High Risk

Very High Risk

Very Low Risk

High Risk

Very High Risk

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Pharmacokinetics

Variable	Value	Unit
Oral Bioavail.	71	%
Molecular weight	64	daltons
T½	432 - 576	hours

References

Follacchio GA, De Feo MS, Monteleone F, De Vincentis G, Liberatore M. Radiopharmaceuticals labelled with copper radionuclides: clinical results in human beings. Curr Radiopharm. 2017 Abstract
Pfeifer A, Knigge U, Mortensen J, Oturai P, Berthelsen AK, Loft A, Binderup T, Rasmussen P, Elema D, Klausen TL, Holm S, von Benzon E, Højgaard L, Kjaer A. Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study. J Nucl Med. 2012 Abstract
Holland JP, Ferdani R, Anderson CJ, Lewis JS. Copper-64 Radiopharmaceuticals for Oncologic Imaging. PET Clin. 2009 Abstract
US.NRC - Howe DB, Beardsley M, Bakhsh S. U.S. Nuclear Regulatory Commission Office of Nuclear Material Safety and Safeguards. Apéndice U, Tabla U.3. Consolidated guidance about materials licenses. Program-specific guidance about medical use licenses. Final report. Appendix U, Table U.3. NUREG-556. Vol.9, Rev 2. 2008 Full text (link to original source) Full text (in our servers)
Johnson PE, Milne DB, Lykken GI. Effects of age and sex on copper absorption, biological half-life, and status in humans. Am J Clin Nutr. 1992 Abstract Full text (link to original source) Full text (in our servers)

Cu-64

High Risk

Poorly safe. Evaluate carefully. Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives). Read the Comment.

Alternatives

Other names

Group

Pharmacokinetics

References

Total visits

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?